Navigation Links
Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
Date:4/17/2009

Pharmacyclics to maintain all US Rights

Conference Call to discuss the company's third quarter financial results is scheduled for April 23, 2009 at 11:00 a.m. EDT (8:00 a.m. PDT).

SUNNYVALE, Calif., April 17 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has entered into a global strategic alliance with Servier, the leading French independent pharmaceutical company. The alliance will focus on the research, development, and commercialization of Pharmacyclics' PCI-24781, an orally active, novel, small molecule inhibitor of Pan HDAC enzymes, that is currently in Phase I/II clinical trials in the United States and being developed for the treatment of solid tumors and hematologic malignancies. Pharmacyclics expects that this alliance will enable it to aggressively pursue its goal of developing and commercializing its innovative anti-cancer Pan HDAC inhibitor agents.

"This alliance with Servier allows us to accelerate our productive discovery efforts, to expand our clinical development capabilities and potentially commercialize our unique and differentiated Pan HDAC inhibitor product outside of the United States in rapid fashion," said Robert W. Duggan, Chairman and Chief Executive Officer of Pharmacyclics. "We are honored to be partnering with the Servier Company, they are incredibly professional in all aspects of their business dealings. Their success and advancement of human healthcare is respected around the world."

Under the terms of the agreement, Servier acquired the exclusive right to develop and commercialize the Pan HDAC inhibitor product worldwide except for the United States and will pay a royalty to Pharmacyclics on sales outside of the United States. Pharmacyclics will continue to own all rights within the United States. Pharmacyclics will re
'/>"/>

SOURCE Pharmacyclics, Inc.

http://www.pharmacyclics.com

SOURCE Pharmacyclics
Copyright©2009 PR Newswire.
All rights reserved


Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
2. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
3. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
4. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
5. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
6. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
7. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
8. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
9. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
10. Premier Research Announces Milestone Investigational New Drug Application
11. PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Encision Inc. (OTCQB:ECIA), a ... dangerous stray electrosurgical burns in minimally invasive surgery, today ... ended June 30, 2014. The Company posted ... net loss of $202 thousand, or $(0.02) per share. ... for a net loss of $311 thousand, or $(0.04) ...
(Date:7/29/2014)... , Next phase of ... has commenced , TPM®/Oxycodone Phase 2a trial ... 2014 , TPM®/Oxymorphone Phase 2 trial to ... Australian drug delivery company, Phosphagenics Limited (ASX: ... programs after its recent announcement of a $19.2 million capital raising. ...
(Date:7/29/2014)...   Health 2.0 announces Bernard Tyson , ... Eric Topol , Patrick Soon-Shiong , and Samsung,s ... 8th Annual Fall Conference this coming Sept. 21-24 in ... 2.0 is set to host the very first Wearable Tech ... Consumer Tech & Wearables: Powering Healthy Lifestyles. The ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4Phosphagenics Provides Update on Opioid Patch Program 2Phosphagenics Provides Update on Opioid Patch Program 3Phosphagenics Provides Update on Opioid Patch Program 4Phosphagenics Provides Update on Opioid Patch Program 5Phosphagenics Provides Update on Opioid Patch Program 6Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3
... Hospira, Inc. (NYSE: HSP ... announced positive results from a Phase I U.S. clinical ... renal (kidney) dysfunction who have anemia. Hospira,s trial met ... and distribution in the body, for Hospira,s EPO and ...
... 6, 2011 Omthera Pharmaceuticals, Inc., a privately-held emerging ... and Chief Executive Officer, will present at the Rodman ... 2011 at 2:25pm ET at the Waldorf Astoria Hotel ... Pharmaceuticals, Inc. Founded in 2008, Omthera ...
Cached Medicine Technology:Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 2Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 3
(Date:7/29/2014)... (PRWEB) July 29, 2014 According to an ... uterine fibroid was recently removed from a 52 year old ... woman, identified only as Latha, reportedly had no idea that ... had been experiencing fatigue and breathlessness for years, but did ... Kumaran Hospital in Chennai only discovered the massive uterine fibroid ...
(Date:7/29/2014)... Francisco, California (PRWEB) July 29, 2014 ... reach USD 9,542.3 million by 2020, growing at an ... to a new study by Grand View Research, Inc. ... of these devices by the geriatric population, along with ... some of the major drivers of this market. In ...
(Date:7/29/2014)... iFitDress.com, one of the most famous dress ... 2014 high low wedding dresses . Aside from that, ... at discounted prices, up to 68% off. All the company’s ... before August 05. , The company’s sales representative is ... dresses. In the new collection, there are numerous great gowns ...
(Date:7/29/2014)... 2014 On Friday, the United States ... week of October 12-18, 2014, as "National Case Management ... improving healthcare outcomes for patients. The resolution was introduced ... (R-AR), with support by the Case Management Society of ... case management professionals for their contributions to healthcare. , ...
(Date:7/29/2014)... California (PRWEB) July 29, 2014 ... of the peer-reviewed journal Lipids in Health and ... value—of Nordic Naturals triglyceride-form best-selling Ultimate Omega®/ProOmega®. Consistently ... according to SPINS scan data, the product was ... to other omega-3 products in the marketplace. The ...
Breaking Medicine News(10 mins):Health News:World’s Largest Uterine Fibroid Removed from Patient 2Health News:World’s Largest Uterine Fibroid Removed from Patient 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 2Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 4Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 5Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 6Health News:2014 High Low Wedding Dresses Provided By iFitDress.com 2Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 2Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 3
... release is available in French . , ... on possible links between cell phone use and brain ... collaborated on the Interphone International Study Group. Jack Siemiatycki, ... epidemiologist at the University of Montreal Hospital Research Center, ...
... HACKENSACK, N.J. (May 17, 2010) John Theurer Cancer Center ... is one of two cancer centers in the tri-state ... DVS (Dose Verification System). John Theurer Cancer Center radiation ... the precise amount of radiation being delivered to tumors ...
... could pave way for tests that predict the illness, researchers ... of serious lung disease in middle age may have genetic ... history of such illnesses in their background, a new study ... might enable doctors to screen for genetic predispositions to serious ...
... ... in the May 17 – 21 event , ... (PRWEB) May 17, 2010 -- Pedego® Electric Bicycles has ... throughout Northern California, has added the Pedego Comfort Cruiser line of electric bikes to ...
... ... keep Affiliates informed on how to achieve the highest conversion performance. , ... Encino, CA (PRWEB) May 14, ... technology concerning the affiliate marketing industry. Founded in 2006, T3Leads has since provided unparalleled ...
... ... Patients Reverse Sun Damage and Restore the Health of Their Skin without Painful Surgery ... Los Angeles ... damage, resulting in wrinkles, sagging, age spots, discoloration and other unsightly symptoms. While a ...
Cached Medicine News:Health News:World's biggest study on cell phones and brain cancer inconclusive 2Health News:John Theurer Cancer Center offers breakthrough radiation measurement technology 2Health News:Lung Disease Can Be Genetic Even Without Family History 2Health News:T3Leads Provides Latest Industry News: Imperative Information to Help Publishers Maximize Profits 2Health News:T3Leads Provides Latest Industry News: Imperative Information to Help Publishers Maximize Profits 3Health News:Epione Reveals a ‘Bright' New Solution for Dull, Sun Damaged Skin 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: